

Tong Lin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11468908/publications.pdf>

Version: 2024-02-01

38
papers

3,869
citations

257450

24
h-index

345221

36
g-index

41
all docs

41
docs citations

41
times ranked

6404
citing authors

#	ARTICLE	IF	CITATIONS
1	The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. <i>Nature Genetics</i> , 2014, 46, 444-450.	21.4	871
2	Novel mutations target distinct subgroups of medulloblastoma. <i>Nature</i> , 2012, 488, 43-48.	27.8	742
3	Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog“Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. <i>Journal of Clinical Oncology</i> , 2015, 33, 2646-2654.	1.6	368
4	Diagnostic accuracy of conventional and cholangioscopy-guided sampling of indeterminate biliary lesions at the time of ERCP: a prospective, long-term follow-up study. <i>Gastrointestinal Endoscopy</i> , 2012, 75, 347-353.	1.0	219
5	Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. <i>Acta Neuropathologica</i> , 2018, 136, 211-226.	7.7	199
6	Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression. <i>Cancer Cell</i> , 2019, 35, 140-155.e7.	16.8	194
7	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 2468-2477.	1.6	160
8	Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). <i>Journal of Clinical Oncology</i> , 2021, 39, 822-835.	1.6	106
9	Prospective evaluation of the clinical utility of ERCP-guided cholangiopancreatography with a new direct visualization system. <i>Gastrointestinal Endoscopy</i> , 2011, 73, 971-979.	1.0	99
10	Heterogeneity within the PF-EPN-B ependymoma subgroup. <i>Acta Neuropathologica</i> , 2018, 136, 227-237.	7.7	86
11	A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. <i>Journal of Neuro-Oncology</i> , 2016, 129, 443-451.	2.9	69
12	FBXO11 promotes ubiquitination of the Snail family of transcription factors in cancer progression and epidermal development. <i>Cancer Letters</i> , 2015, 362, 70-82.	7.2	68
13	Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children. <i>Neuro-Oncology</i> , 2015, 17, 882-888.	1.2	64
14	Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. <i>Cancer Cell</i> , 2021, 39, 1519-1530.e4.	16.8	64
15	A Phase I Trial of Imetelstat in Children with Refractory or Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Study (ADVL1112). <i>Clinical Cancer Research</i> , 2013, 19, 6578-6584.	7.0	60
16	Genomic analysis demonstrates that histologically-defined astroblastomas are molecularly heterogeneous and that tumors with MN1 rearrangement exhibit the most favorable prognosis. <i>Acta Neuropathologica Communications</i> , 2019, 7, 42.	5.2	57
17	Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. <i>Neuro-Oncology</i> , 2021, 23, 1360-1370.	1.2	46
18	The Malignant Brain Tumor (MBT) Domain Protein SFMBT1 Is an Integral Histone Reader Subunit of the LSD1 Demethylase Complex for Chromatin Association and Epithelial-to-mesenchymal Transition. <i>Journal of Biological Chemistry</i> , 2013, 288, 27680-27691.	3.4	42

#	ARTICLE	IF	CITATIONS
19	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 807-821.	1.6	40
20	Gliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas. <i>Acta Neuropathologica</i> , 2016, 131, 299-307.	7.7	38
21	Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials. <i>Acta Neuropathologica</i> , 2020, 139, 259-271.	7.7	36
22	Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas. <i>Frontiers in Oncology</i> , 2014, 4, 67.	2.8	31
23	Comprehensive molecular characterization of pediatric radiation-induced high-grade glioma. <i>Nature Communications</i> , 2021, 12, 5531.	12.8	31
24	Forty-five patient-derived xenografts capture the clinical and biological heterogeneity of Wilms tumor. <i>Nature Communications</i> , 2019, 10, 5806.	12.8	27
25	Malignant rhabdoid tumors originating within and outside the central nervous system are clinically and molecularly heterogeneous. <i>Acta Neuropathologica</i> , 2018, 136, 315-326.	7.7	26
26	Bithalamic gliomas may be molecularly distinct from their unilateral high-grade counterparts. <i>Brain Pathology</i> , 2018, 28, 112-120.	4.1	26
27	Pubertal development and primary ovarian insufficiency in female survivors of embryonal brain tumors following risk-adapted craniospinal irradiation and adjuvant chemotherapy. <i>Pediatric Blood and Cancer</i> , 2015, 62, 329-334.	1.5	20
28	Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 362-371.	2.4	17
29	Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1116-1122.	3.3	15
30	Exposure-Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing. <i>Clinical Cancer Research</i> , 2020, 26, 1563-1573.	7.0	14
31	A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. <i>Clinical Cancer Research</i> , 2021, 27, 2442-2451.	7.0	13
32	DNA Methylation Profiling Reveals Prognostically Significant Groups in Pediatric Adrenocortical Tumors: A Report From the International Pediatric Adrenocortical Tumor Registry. <i>JCO Precision Oncology</i> , 2019, 3, 1-21.	3.0	6
33	Outcome and molecular analysis of young children with choroid plexus carcinoma treated with non-myeloablative therapy: results from the SJYC07 trial. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa168.	0.7	6
34	The molecular characteristics of low-grade and high-grade areas in desmoplastic infantile astrocytoma/ganglioglioma. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	3.2	5
35	HGG-06. Phase 2 Study of Veliparib and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma without H3 K27M or BRAF Mutations: A Report from the Children's Oncology Group ACNS1721 Study. <i>Neuro-Oncology</i> , 2022, 24, i60-i61.	1.2	1
36	OR02-1 DNA Methylation Profiling in Pediatric Adrenocortical Tumors Reveals Distinct Methylation Signatures with Prognostic Significance: A Report from the International Pediatric Adrenocortical Tumor Registry. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0

#	ARTICLE	IF	CITATIONS
37	BIOM-36. SERIAL ASSESSMENT OF MEASURABLE RESIDUAL DISEASE IN MEDULLOBLASTOMA LIQUID BIOPSIES. Neuro-Oncology, 2021, 23, vi18-vi19.	1.2	0
38	QOL-17. Neurocognitive outcomes after treatment for medulloblastoma with reduced primary site target volume margins. Neuro-Oncology, 2022, 24, i137-i137.	1.2	0